The Journal of Experimental Medicine
PBL InterferonSource
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 6 March 2006 doi:10.1084/jem.20052369
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 203, Number 3, 699-710
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 2398K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gadola, S. D.
Right arrow Articles by Jones, E. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gadola, S. D.
Right arrow Articles by Jones, E. Y.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ARTICLE

 Structure and binding kinetics of three different human CD1d–{alpha}-galactosylceramide–specific T cell receptors

Stephan D. Gadola1,2, Michael Koch3, Jon Marles-Wright3, Nikolai M. Lissin4, Dawn Shepherd2, Gediminas Matulis1, Karl Harlos3, Peter M. Villiger1, David I. Stuart3, Bent K. Jakobsen4, Vincenzo Cerundolo2, and E. Yvonne Jones3

1 Department of Rheumathology and Clinical Immunology, University of Bern, Inselspital, Berne CH-3010, Switzerland
2 Cancer Research UK Tumor Immunology Group, The Weatherall Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, Oxford OX3 9DS, UK
3 Cancer Research UK Receptor Structure Research Group, The Henry Wellcome Building for Genomic Medicine, Headington, Oxford OX3 7BN, UK
4 Avidex, OX14 4RX Abingdon, UK

CORRESPONDENCE E.Y. Jones: yvonne{at}strubi.ox.ac.uk OR S.D. Gadola: stephan.gadola{at}insel.ch

Invariant human TCR V{alpha}24-J{alpha}18+/Vß11+ NKT cells (iNKT) are restricted by CD1d–{alpha}-glycosylceramides. We analyzed crystal structures and binding characteristics for an iNKT TCR plus two CD1d–{alpha}-GalCer–specific Vß11+ TCRs that use different TCR V{alpha} chains. The results were similar to those previously reported for MHC–peptide-specific TCRs, illustrating the versatility of the TCR platform. Docking TCR and CD1d–{alpha}-GalCer structures provided plausible insights into their interaction. The model supports a diagonal orientation of TCR on CD1d and suggests that complementarity determining region (CDR)3{alpha}, CDR3ß, and CDR1ß interact with ligands presented by CD1d, whereas CDR2ß binds to the CD1d {alpha}1 helix. This docking provides an explanation for the dominant usage of Vß11 and Vß8.2 chains by human and mouse iNKT cells, respectively, for recognition of CD1d–{alpha}-GalCer.

Abbreviations used: {alpha}-GalCer, {alpha}-galactosylceramide; CDR, complementarity determining region; CNS, Crystallography and NMR system; DN, double negative; ds, disulfide-linked; iNKT, invariant NKT; J, junctional; PC, phosphatidylcholine; rmsd, root mean square deviation; V, variable.

V. Cerundolo and E.Y. Jones share senior authorship.

S.D. Gadola, M. Koch, and J. Marles-Wright contributed equally to this work.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS